Lartruvo olaratumab regulatory update

FDA granted accelerated approval to Lartruvo olaratumab from Eli Lilly in combination with doxorubicin to treat to treat advanced soft tissue sarcoma patients who cannot be cured with radiation or surgery and for whom chemotherapy is appropriate. Lilly said Lartruvo would be available “in the coming weeks” and that the company has not yet set the drug’s price. The human IgG1 mAb targeting platelet derived growth factor receptor A (PDGFRA; PDGFR2; CD140A) has breakthrough therapy, Fast Track and Orphan Drug status from FDA in the indication...